A detailed history of Baird Financial Group, Inc. transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Baird Financial Group, Inc. holds 14,117 shares of PCVX stock, worth $1.21 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14,117
Previous 19,133 26.22%
Holding current value
$1.21 Million
Previous $1.44 Million 11.57%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$70.52 - $117.12 $353,728 - $587,473
-5,016 Reduced 26.22%
14,117 $1.61 Million
Q2 2024

Aug 13, 2024

BUY
$60.06 - $78.77 $159,759 - $209,528
2,660 Added 16.15%
19,133 $1.44 Million
Q1 2024

May 14, 2024

SELL
$59.79 - $81.05 $1.61 Million - $2.19 Million
-26,984 Reduced 62.09%
16,473 $1.13 Million
Q4 2023

Feb 14, 2024

BUY
$45.35 - $63.41 $1.97 Million - $2.76 Million
43,457 New
43,457 $2.73 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.1B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Baird Financial Group, Inc. Portfolio

Follow Baird Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Baird Financial Group, Inc. with notifications on news.